Survodutide
Dual glucagon/GLP-1 receptor agonist studied in clinical trials.
Search names: BI 456906
Evidence
Catalogue entry · see sources
Describes the linked sources, not an overall score for product quality or effectiveness.Half-life
Statistics reference: About 6.1 days
Human information in catalogueContext and sources for the statistics reference
Catalogue quick fact; its text rounds to about six days from early human trials.
About 6.1 days · Catalogue information from PeptideTracker.ai; read the limitation above. PeptideTracker.ai · Survodutide ↗
Half-life, duration of effect and shelf life are different measures. Catalogue values may differ between variants and administration routes. Curves continue to use their stated statistics reference.
Adverse effects and limitations
Adverse effects are not fully mapped in this entry. Consult the sources for the specific compound and use.
Sources and further reading
Vital · user-supplied screen recordings, 1 Nov 2026
Find researchPubMed · Survodutide↗Research information, not a personal dosing plan. Last reviewed: 2026-11-01.